NasdaqGS:AMLXPharmaceuticals
The Bull Case For Amylyx Pharmaceuticals (AMLX) Could Change Following Narrower Losses And New Shelf Filings
Amylyx Pharmaceuticals reported fourth-quarter 2025 results on March 3, 2026, with net loss narrowing to US$33.00 million from US$37.55 million a year earlier and full-year net loss improving to US$144.74 million from US$301.74 million, alongside reduced losses per share.
On the same day, the company filed new shelf registrations for common stock, preferred stock, debt, warrants, and units, expanding its flexibility to raise capital to support its late-stage clinical pipeline and future...